Intec Pharma Ltd. (NASDAQ: NTEC) will present at the H.C. Wainwright 22nd Annual Global Investment Conference from September 14–16, 2020. The company’s presentation is scheduled for September 15, 2020, at 4:30 pm (ET), led by Jeffrey A. Meckler, Vice Chairman and CEO. This virtual event includes corporate presentations and one-on-one investor meetings. The presentation will be livestreamed on Intec's official website and archived for future access. Intec focuses on developing drugs through its Accordion Pill technology for conditions like Parkinson's disease.
Intec Pharma Ltd. (NASDAQ: NTEC) announced the completion of a registered direct offering with Aspire Capital Fund for 7,125,000 ordinary shares at $0.3511 each, along with pre-funded warrants at $0.3411. The offering, expected to close by August 10, 2020, will yield gross proceeds of approximately $4.9 million, after a commitment fee of $250,000. Funds will support research and development activities, alongside working capital. This issuance is part of a previously filed shelf registration statement with the SEC.
Intec Pharma Ltd. (NASDAQ: NTEC) reports a significant decrease in expenses for Q2 2020, with research and development costs dropping by 84% to $1.3 million, and general and administrative expenses down 24% to $1.6 million. This resulted in a net loss of $2.9 million, a 71% decline from last year. The company reported cash and equivalents of $13.8 million as of June 30. Financial support from recent offerings, including $10.6 million in financing, strengthens the company's position amid ongoing clinical developments, including the AP-THC program.
Intec Pharma Ltd. (NASDAQ: NTEC) announced a registered direct offering of 16,291,952 ordinary shares at a price of $0.30690 per share, expected to close on May 6, 2020. The offering aims to raise approximately $5.0 million to fund research and development and for working capital. Investors will also receive unregistered warrants to purchase an additional 8,145,976 shares at an exercise price of $0.245. H.C. Wainwright & Co. is the exclusive placement agent for this transaction.